Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash from Operations: 2014-2024

Historic Cash from Operations for AC Immune (ACIU) over the last 11 years, with Dec 2024 value amounting to $75.2 million.

  • AC Immune's Cash from Operations fell 315.37% to -$67.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.1 million, marking a year-over-year decrease of 316.62%. This contributed to the annual value of $75.2 million for FY2024, which is 209.60% up from last year.
  • AC Immune's Cash from Operations amounted to $75.2 million in FY2024, which was up 209.60% from -$68.6 million recorded in FY2023.
  • In the past 5 years, AC Immune's Cash from Operations registered a high of $75.2 million during FY2024, and its lowest value of -$76.4 million during FY2022.
  • Moreover, its 3-year median value for Cash from Operations was -$68.6 million (2023), whereas its average is -$23.3 million.
  • As far as peak fluctuations go, AC Immune's Cash from Operations slumped by 217.98% in 2020, and later skyrocketed by 209.60% in 2024.
  • Over the past 5 years, AC Immune's Cash from Operations (Yearly) stood at -$65.8 million in 2020, then declined by 9.19% to -$71.9 million in 2021, then decreased by 6.23% to -$76.4 million in 2022, then increased by 10.20% to -$68.6 million in 2023, then skyrocketed by 209.60% to $75.2 million in 2024.